RealFeedApp Partners launched two oncology R&D programs
Partners completed target nominations for two oncology programs, triggering the first payment under the $888 million deal.
- Field
- business and funding
- What they did
- Insilico Medicine achieved a first milestone in its multi-year AI-driven collaboration with Servier, triggering an undisclosed payment. The partners launched two oncology R&D programs and completed target nominations for both.
- Why it matters
- The collaboration, valued at up to $888 million with $32 million in upfront payments, allows Insilico to focus on AI-driven discovery while Servier handles clinical validation and commercialization.
#insilico#servier#generative ai#oncology#drug discovery
